Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from AstraZeneca

Business news live: Price of silver shoots to 14-year high and FTSE 100 falls before weekend

Stock markets updates and business news from Friday

The Independent UK

Cathie Wood Vs. Jim Cramer: TV Host Says Top Ark AI Pick 'Losing Money Hand Over Fist'

When it comes to artificial intelligence stocks, there are multiple that are found in the various portfolios of Ark Funds, led by Cathie Wood.

Benzinga

AstraZeneca’s stock market exit would be devastating blow, warns ex-chancellor

The UK is ‘a hostile environment’ for innovative, high-tech growth companies, the Government has been told.

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks fade as tariff deadline looms large

US President Donald Trump said he plans to start sending letters informing trading partners of their tariff rates.

Evening Standard

If AstraZeneca goes to the US, it will be a major blow for London and Labour

Move would deprive LSE of its biggest star and could topple a key pillar of the government’s industrial strategy

The Guardian - UK

What AstraZeneca could cost London stock market if it moves to US

IN FULL

The Independent UK

Fears over £160bn blow to London’s stock market as AstraZeneca considers listing move to US

CEO Pascal Soriot has not hidden his annoyance at taxes and regulations the pharmaceutical firm have to navigate

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Business news live: Gilt yields spike on Reeves exit speculation and CEO of AstraZeneca discusses leaving London

Stock markets updates and business news from Wednesday

The Independent UK

AstraZeneca boss ‘wants to shift stock market listing to US’

Report claims CEO Pascal Soriot talked in private about moving UK’s most valuable listed company and considered shifting its domicile

The Guardian - UK

IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA

IonQ just hit investors with two pieces of big news. One shows proof of the company's tech being useful near-term. The other looks to aid its long-term goals.

MarketBeat

‘Transformational’ new breast cancer drug could halt the growth of tumours

A trial funded by AstraZeneca found the drug is effective in stopping cancer cells from using hormones to grow

The Independent UK

Short Sellers Are Taking Aim at Buy-Rated Tempus AI. Should You Buy TEM Stock Here?

Tempus AI stock fell over 19% after Spruce Point Capital released a short report. Can TEM stock recover?

Barchart

How the love story between von der Leyen and Pfizer turned sour

From making her Europe’s vaccine saviour to becoming a skeleton in her closet: All the ebbs and flows in the love story between Ursula von der Leyen and big pharma Pfizer.

Euronews

Drug price cuts: what is Trump planning and what will it mean for big pharma?

President has directed Robert Kennedy to send price targets to industry, with slimming drugs thought to be included

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Tempus AI Stock: Time to Double Down or Cut and Run?

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point to significant upside potential.

International Business Times

AstraZeneca Moves Some Production To US Amid Tariff Threat

British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the United States, ahead of President Donald Trump's possible tariffs on the sector.

The Guardian - UK

Drugmaker AstraZeneca shifts more production to US amid Trump tariffs

UK and rest of Europe risk losing out to US and China unless they ramp up spending on new medicines, says CEO Pascal Soriot

Evening Standard

AstraZeneca plots US expansion despite Trump tariff threat

The drug maker said it is ‘firmly committed to investing and growing in the US’ amid potential import tariffs on the pharmaceutical industry.

Get all your
news in one place.

100's of premium titles.
One news app.

Al Jazeera

Trade war with China to hit US healthcare

Without a carve-out for tariff exceptions for pharmaceuticals, prices will skyrocket for US patients, experts warn.

Evening Standard

Drug firm bosses call for price increases in Europe amid tariff uncertainty

The boss of AstraZeneca said Europe should increase spending on health treatment in line with recent commitments on defence.

MarketBeat

Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal

Cellectis, backed by AstraZeneca funding and a multi-year cash runway, is advancing its prioritized allogeneic CAR-T pipeline toward pivotal 2025 milestones.

The Independent UK

Pharmaceuticals are the next Trump tariff battleground - what will they mean for the NHS?

TRUMP TARIFFS: UK-based drug companies AstraZeneca and GSK could be affected by Trump’s next decision, as Karl Matchett reports

The Guardian - UK

Ministers in ‘active conversation’ with UK drug firms over potential tariffs

Government seeks ways to shield industry from possible US levies amid concern over effect on medicine supply

The Independent UK

Scramble underway to stop Trump tariffs hitting Britain’s pharmaceutical industry

Donald Trump has warned tariffs on pharmaceuticals would come ‘in the not-too-distant future’

Evening Standard

UK scrambling to get Donald Trump to slash tariffs to zero, says minister as US threatens medicines levies

Tariffs on Britain’s pharmaceutical industry could deal a severe blow, potentially costing firms billions of pounds

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.